PXD016088-2

PXD016088 is an original dataset announced via ProteomeXchange.

Title	Proteomic profiling of murine melanoma treated with bone morphogenetic protein (BMP) signaling inhibitor
Description	Melanoma is a highly aggressive skin cancer, which has the fastest and second fastest growing incidence of any cancer in men and women, respectively. Although melanoma accounts for 5% of skin cancers, it is responsible for 80% of deaths related to skin cancers. The lifetime risk of melanoma is currently estimated to be 1 in 75 and is rising every year. The present study shows that inhibition of bone morphogenetic protein (BMP) signaling pathway is a potential target for treating metastatic melanoma. To characterize the underlying signaling mechanism, comparative proteomic profile of the mouse melanoma tissue treated with and BMP inhibitor (LDN193189) with untreated controls was performed using liquid chromatography-tandem mass spectrometry. Our mass spectrometry data analysis leads to identification of a total of 3231 nonredundant proteins. Of the 3231 proteins, 117 were up-regulated (fold change≥ 1.5) while 14 were down-regulated (fold change ≤ 0.66). Pathway enrichment analysis showed that altered proteins were primarily grouped into: regulation of actin cytoskeleton, phagosomes, proteoglycans in cancer, Focal adhesion, ECM receptor interaction and fatty acid metabolism pathway. Our studies suggest that inhibition of the BMP signaling cascade with small molecule inhibitors decreased the expression of the MT1 and MT2 (metallothionine 1 and 2) which are well known for the antiapoptotic, antioxidant, proliferative, and angiogenic effects in cancer.
HostingRepository	PRIDE
AnnounceDate	2024-10-22
AnnouncementXML	Submission_2024-10-22_05:31:30.346.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Keshava Prasad T. S.
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: 10090;
ModificationList	TMT6plex-126 reporter+balance reagent acylated residue; iodoacetamide derivatized residue
Instrument	Q Exactive Plus

Revision	Datetime	Status	ChangeLog Entry
0	2019-10-31 02:17:11	ID requested
1	2022-02-15 09:24:21	announced
⏵ 2	2024-10-22 05:31:38	announced	2024-10-22: Updated project metadata.

Kalal BS, Modi PK, Upadhya D, Saha P, Prasad TSK, Pai VR, Inhibition of bone morphogenetic proteins signaling suppresses metastasis melanoma: a proteomics approach. Am J Transl Res, 13(10):11081-11093(2021) [pubmed]

submitter keyword: cancer, bRPLC, skin, Protein Profiling,Melanoma, mouse

T. S. Keshava Prasad
contact affiliation	Professor and Deputy Director, Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre. Yenepoya (Deemed to be University), University Road, Deralakatte, Mangalore 575018, India
contact email	keshav@yenepoya.edu.in
lab head
Keshava Prasad T. S.
contact affiliation	Institute of Bioinformatics, Bangalore, Karnataka, India.
contact email	keshav@ibioinformatics.org
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/02/PXD016088

PRIDE project URI

• PRIDE
  1. PXD016088
     1. Label: PRIDE project
     2. Name: Proteomic profiling of murine melanoma treated with bone morphogenetic protein (BMP) signaling inhibitor